Israeli biotech company Alpha DaRT Secures Cross-Border Funding
Categories: Capital Markets, Hi-Tech
Israeli medical technology company Alpha DaRT, a pioneer in alpha-radiation-based cancer treatments, has completed a cross-border offering to support the continued development and expansion of its oncology platform.
The transaction strengthens the company’s position in the global life sciences industry and reflects growing investor confidence in breakthrough radiation therapies.
Latham & Watkins advised on the deal, with a team led by London partner Joshua Kiernan and Tel Aviv counsel Michael Rosenberg. The firm’s cross-border capabilities continue to play a key role in advancing innovative biotech ventures from lab to market.
